AR and prostate neoplasm: The other possible binding partners of RORα1 via NTD underlying the anti-tumor effect of RORα1 warrants further study, but it is plausible that effective suppression of prostate tumor progression that was not fully achieved by treatment with AR-targeted therapies might lead to better targeting approaches through Wnt/β-catenin inhibition by RORα1 peptide therapies.